A prospective study on clinical response and cell-mediated immunity of pemphigus patients treated with rituximab

Archives of Dermatological Research

Volumn 306, Issue 1, 2014, Pages 67-74

  Leshem, Y A ^a,b   David, M ^a,b   Hodak, E ^a,b   Waitman, D A ^c   Vardy, D ^c,d   Israeli, M ^a   Eskin Schwartz, M ^a   Bergman, R ^e,f   Mimouni, D ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c Leumit Health Care Services   (Israel)

^d BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^e RAMBAM MEDICAL CENTER   (Israel)

^f TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Cylex; ImmuKnow; MabThera; Pemphigus; Rituximab

Indexed keywords

AZATHIOPRINE; DIPHENHYDRAMINE; METHYLPREDNISOLONE; PARACETAMOL; PREDNISONE; RITUXIMAB;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; DISEASE CONTROL; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MIDDLE AGED; PEMPHIGUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE RISK; REMISSION; REVIEW;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; AUTOANTIBODIES; B-LYMPHOCYTES; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; MALE; MIDDLE AGED; PEMPHIGUS; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME;

EID: 84891869456     PISSN: 03403696     EISSN: 1432069X     Source Type: Journal    
DOI: 10.1007/s00403-013-1355-4     Document Type: Review

References (36)

1. Akimoto M, Yunoue S, Otsubo H et al (2013) Assessment of peripheral blood CD4+ adenosine triphosphate activity in patients with rheumatoid arthritis. Mod Rheumatol 23:19-27
2. Amagai M, Klaus-Kovtun V, Stanley JR (1991) Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 67:869-877 (Pubitemid 121001501)
3. Beissert S, Mimouni D, Kanwar AJ et al (2010) Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. J Invest Dermatol 130:2041-2048
4. Carson KR, Evens AM, Richey EA et al (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113:4834-4840
5. Cianchini G, Lupi F, Masini C et al (2012) Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up. J Am Acad Dermatol 67:617-622
6. Cohen SB, Emery P, Greenwald MW, et al., REFLEX Trial Group (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54:2793-2806 (Pubitemid 44497758)
7. Emery P, Fleischmann R, Filipowicz-Sosnowska A, DANCER Study Group (2006) The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54:1390-1400
8. Eming R, Nagel A, Wolff-Franke S et al (2008) Rituximab exerts a dual effect in pemphigus vulgaris. J Invest Dermatol 128:2850-2858
9. Furst DE, Keystone EC, Fleischmann R et al (2009) Updated consensus statement on biological agents for the treatment of rheumatic diseases. Ann Rheum Dis 69(Suppl 1):i2-i29
10. Ge S, Pao A, Vo A et al (2011) Immunologic parameters and viral infections in patients desensitized with intravenous immunoglobulin and rituximab. Transpl Immunol 24:142-148
11. Haghikia A, Perrech M, Pula B et al (2011) Functional energetics of CD4+ -cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders. PLoS ONE 20:e18506
12. Israeli M, Ben-Gal T, Yaari V et al (2010) Individualized immune monitoring of cardiac transplant recipients by noninvasive longitudinal cellular immunity tests. Transplantation 89:968-976
13. Israeli M, Klein T, Brandhorst G, Oellerich M (2012) Confronting the challenge: individualized immune monitoring after organ transplantation using the cellular immune function assay. Clin Chim Acta 413:1374-1378
14. Joly P, Mouquet H, Roujeau J-C et al (2007) A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 357:545-552 (Pubitemid 47236279)
15. Kasperkiewicz M, Shimanovich I, Ludwig RJ et al (2011) Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol 65:552-558
16. Kim JH, Kim YH, Kim MR, Kim SC (2011) Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients. Br J Dermatol 165:646-651
17. Kowalski RJ, Post DR, Mannon RB et al (2006) Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 82:663-668 (Pubitemid 44395237)
18. Kowalski RJ, Post D, Schneider MC et al (2003) Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant 17:77-88 (Pubitemid 36833776)
19. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC (2006) Repopulation of B lymphocytes in peripheral blood following B lymphocyte depletion with rituximab in rheumatoid arthritis. Arthritis Rheum 54:613-620 (Pubitemid 43228639)
20. Leshem YA, Hodak E, David M et al (2013) Successful treatment of pemphigus with bi-weekly 1-g infusions of rituximab: a retrospective study of 47 patients. J Am Acad Dermatol 68:404-411
21. Lester RS, Knowles SR, Shear NH (1998) The risks of systemic corticosteroid use. Dermatol Clin 16:277-278 (Pubitemid 28205024)
22. Martin LK, Werth V, Villanueva E, et al (2009) Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev (1):CD006263
23. McLaughlin P, White CA, Grillo-Lopez AJ, Maloney DG (1998) Clinical status and optimal use of rituximab for B-cell lymphomas. Oncology (Williston Park) 12:1763-1769
24. Mouquet H, Musette P, Gougeon ML et al (2008) B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. J Invest Dermatol 128:2859-2869
25. Murrell DF, Dick S, Ahmed AR et al (2008) Consensus statement on definitions of disease endpoints and therapeutic response for pemphigus. J Am Acad Dermatol 58:1043-1046
26. Nagel A, Hertl M, Eming R (2009) B-cell-directed therapy for inflammatory skin diseases. J Invest Dermatol 129:289-301
27. Nickel P, Bestard O, Volk HD, Reinke P (2009) Diagnostic value of T-cell monitoring assays in kidney transplantation. Curr Opin Organ Transplant 14:426-431
28. Nishifuji K, Amagai M, Kuwana M et al (2000) Detection of antigen-specific B cells in patients with pemphigus vulgaris by enzyme-linked immunospot assay: requirement of T cell collaboration for autoantibody production. J Invest Dermatol 114:88-94 (Pubitemid 30195978)
29. Parzen M, Lipsitz S, Metters R, Fitzmaurice G (2010) Correlation when data are missing. J Oper Res Soc 61:1049-1056
30. Rosenbach M, Murell DF, Bystryn JC et al (2009) Reliability and convergent validity of two outcome instruments for pemphigus. J Invest Dermatol 129:2404-2410
31. Salopek TG, Logsetty S, Tredget EE (2002) Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol 47:785-788 (Pubitemid 35239347)
32. Schmidt E, Goebeler M, Zillikens D (2009) Rituximab in severe pemphigus. Ann NY Acad Sci 1173:683-691
33. Sottong PR, Rosebrock JA, Britz JA, Kramer TR (2000) Measurement of T lymphocyte responses in whole-blood cultures using newly synthesized DNA and ATP. Clin Diagn Lab Immunol 7:307-311 (Pubitemid 30132130)
34. Stanley JR (1993) Cell adhesion molecules as targets of autoantibodies in pemphigus and pemphigoid, bullous diseases due to defective epidermal cell adhesion. Adv Immunol 53:291-325
35. Stanley JR (1989) Pemphigus and pemphigoid as paradigms of organ-specific, autoantibody-mediated diseases. J Clin Invest 83:1443-1448 (Pubitemid 19124095)
36. Takahashi H, Kuwana M, Amagai M (2009) A single helper T cell clone is sufficient to commit polyclonal naive B cells to produce pathogenic IgG in experimental pemphigus vulgaris. J Immunol 182:1740-1745